NO762923L - - Google Patents
Info
- Publication number
- NO762923L NO762923L NO762923A NO762923A NO762923L NO 762923 L NO762923 L NO 762923L NO 762923 A NO762923 A NO 762923A NO 762923 A NO762923 A NO 762923A NO 762923 L NO762923 L NO 762923L
- Authority
- NO
- Norway
- Prior art keywords
- culture
- strain
- salts
- compound
- liters
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 241000946829 Streptomyces mutabilis Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 231100000219 mutagenic Toxicity 0.000 claims description 2
- 230000003505 mutagenic effect Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
- 241001446247 uncultured actinomycete Species 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229910000355 cerium(IV) sulfate Inorganic materials 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002633 shock therapy Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1140575 | 1975-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO762923L true NO762923L (fr) | 1977-03-03 |
Family
ID=4373179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO762923A NO762923L (fr) | 1975-09-02 | 1976-08-25 |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS5231886A (fr) |
| AT (1) | ATA646276A (fr) |
| AU (1) | AU1737176A (fr) |
| BE (1) | BE845708A (fr) |
| DE (1) | DE2638400A1 (fr) |
| DK (1) | DK380076A (fr) |
| ES (1) | ES451091A1 (fr) |
| FI (1) | FI55051C (fr) |
| FR (1) | FR2322596A1 (fr) |
| IL (1) | IL50388A0 (fr) |
| NL (1) | NL7609615A (fr) |
| NO (1) | NO762923L (fr) |
| NZ (1) | NZ181899A (fr) |
| PT (1) | PT65539B (fr) |
| SE (1) | SE7609493L (fr) |
| SU (1) | SU643085A3 (fr) |
| ZA (1) | ZA765281B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4830967A (en) * | 1985-05-28 | 1989-05-16 | Eli Lilly And Company | Process for producing antibiotic A80438 |
| DE3677844D1 (de) * | 1985-05-28 | 1991-04-11 | Lilly Co Eli | Polyether-antibiotikum und verfahren zu seiner herstellung. |
| US4967717A (en) * | 1987-11-20 | 1990-11-06 | Mitsubishi Denki Kabushiki Kaisha | Abnormality detecting device for an EGR system |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2097053A2 (en) * | 1970-07-30 | 1972-03-03 | Agronomique Inst Nat Rech | Grisorixin - insecticidal and acaricidal antibiotic |
-
1976
- 1976-08-24 DK DK380076A patent/DK380076A/da unknown
- 1976-08-24 FI FI762420A patent/FI55051C/fi not_active IP Right Cessation
- 1976-08-25 NO NO762923A patent/NO762923L/no unknown
- 1976-08-26 DE DE19762638400 patent/DE2638400A1/de active Pending
- 1976-08-26 SE SE7609493A patent/SE7609493L/xx unknown
- 1976-08-30 NL NL7609615A patent/NL7609615A/xx not_active Application Discontinuation
- 1976-08-30 ES ES451091A patent/ES451091A1/es not_active Expired
- 1976-08-31 BE BE170238A patent/BE845708A/fr unknown
- 1976-08-31 NZ NZ181899A patent/NZ181899A/xx unknown
- 1976-08-31 PT PT65539A patent/PT65539B/fr unknown
- 1976-08-31 IL IL50388A patent/IL50388A0/xx unknown
- 1976-08-31 SU SU762391602A patent/SU643085A3/ru active
- 1976-09-01 JP JP51103767A patent/JPS5231886A/ja active Pending
- 1976-09-01 AU AU17371/76A patent/AU1737176A/en not_active Expired
- 1976-09-01 AT AT646276A patent/ATA646276A/de not_active Application Discontinuation
- 1976-09-02 ZA ZA00765281A patent/ZA765281B/xx unknown
- 1976-09-02 FR FR7626459A patent/FR2322596A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| SU643085A3 (ru) | 1979-01-15 |
| IL50388A0 (en) | 1976-10-31 |
| DE2638400A1 (de) | 1977-03-10 |
| FI55051C (fi) | 1979-05-10 |
| ATA646276A (de) | 1979-10-15 |
| FR2322596B1 (fr) | 1978-12-22 |
| SE7609493L (sv) | 1977-03-03 |
| NZ181899A (en) | 1978-11-13 |
| FR2322596A1 (fr) | 1977-04-01 |
| ES451091A1 (es) | 1977-12-01 |
| FI762420A (fr) | 1977-03-03 |
| BE845708A (fr) | 1977-02-28 |
| PT65539B (fr) | 1978-05-10 |
| JPS5231886A (en) | 1977-03-10 |
| AU1737176A (en) | 1978-03-09 |
| PT65539A (fr) | 1976-09-01 |
| ZA765281B (en) | 1978-04-26 |
| FI55051B (fi) | 1979-01-31 |
| NL7609615A (nl) | 1977-03-04 |
| DK380076A (da) | 1977-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4738958A (en) | Ansamycin antibiotic and its use as a medicament | |
| NO783545L (no) | Fremgangsmaate til fremstilling av deoksynarasinantibiotisk kompleks | |
| NO762923L (fr) | ||
| US4440857A (en) | Process for preparing mycarosyltylactone | |
| EP0327009A1 (fr) | WS-9326A, WS-9326B et leurs dérivés | |
| US2799690A (en) | 3-keto-16alpha, 20beta-dihydroxy pregnenes | |
| US4401812A (en) | Anthracycline antibiotics | |
| US4011140A (en) | Process for producing antitumor compound | |
| US5217882A (en) | Microbial transformation process for producing antihypertensive N2 -glucuronide products | |
| US3335059A (en) | And method of producing | |
| JPH0578322A (ja) | 新規抗生物質ｓｆ２７３８物質及びその製造法並びに制癌剤 | |
| US5223519A (en) | 4-hydroxypyridine derivatives, useful for treating circulatory diseases | |
| US5214153A (en) | Actinoplanes transformation process anti-hypertensive compound and method of use thereas | |
| US4206129A (en) | Antibiotic SM-173B | |
| US3310468A (en) | Antifungal antibiotic rutamycin and process for the production thereof | |
| KR820000295B1 (ko) | 코엔자임 q의 제조방법 | |
| US3835170A (en) | Hypotensive agent, oudenone, its salts and processes for production and preparation thereof | |
| US6521600B1 (en) | Compound, WF002, production thereof and use thereof | |
| EP0180045A2 (fr) | Dérivés de la benzanthrine | |
| US3088872A (en) | Ayamycin, a new antibiotic and process for producing the same | |
| JPH0662632B2 (ja) | 新規抗生物質ａ１−ｒ２３９７物質及びその製造法 | |
| JP2594085B2 (ja) | 新規抗腫瘍抗生物質ｓｆ２５７５物質ならびにその製造法 | |
| JP2578486B2 (ja) | 新規物質ｋｓ―５０２ | |
| JPH0359911B2 (fr) | ||
| EP0064555B1 (fr) | Antibiotique 5057b |